Download MendeleyDual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism.
Overdijk, M.B., Strumane, K., Beurskens, F.J., Ortiz Buijsse, A., Vermot-Desroches, C., Vuillermoz, B.S., Kroes, T., de Jong, B., Hoevenaars, N., Hibbert, R.G., Lingnau, A., Forssmann, U., Schuurman, J., Parren, P.W.H.I., de Jong, R.N., Breij, E.C.W.(2020) Mol Cancer Ther 19: 2126-2138
- PubMed: 32847982
- DOI: https://doi.org/10.1158/1535-7163.MCT-20-0044
- Primary Citation of Related Structures:
6T3J - PubMed Abstract:
Higher-order death receptor 5 (DR5) clustering can induce tumor cell death; however, therapeutic compounds targeting DR5 have achieved limited clinical efficacy. We describe HexaBody-DR5/DR5, an equimolar mixture of two DR5-specific IgG1 antibodies with an Fc-domain mutation that augments antibody hexamerization after cell surface target binding. The two antibodies do not compete for binding to DR5 as demonstrated using binding competition studies, and binding to distinct epitopes in the DR5 extracellular domain was confirmed by crystallography. The unique combination of dual epitope targeting and increased IgG hexamerization resulted in potent DR5 agonist activity by inducing efficient DR5 outside-in signaling and caspase-mediated cell death. Preclinical studies in vitro and in vivo demonstrated that maximal DR5 agonist activity could be achieved independent of Fc gamma receptor-mediated antibody crosslinking. Most optimal agonism was observed in the presence of complement complex C1, although without inducing complement-dependent cytotoxicity. It is hypothesized that C1 may stabilize IgG hexamers that are formed after binding of HexaBody-DR5/DR5 to DR5 on the plasma membrane, thereby strengthening DR5 clustering and subsequent outside-in signaling. We observed potent antitumor activity in vitro and in vivo in large panels of patient-derived xenograft models representing various solid cancers. The results of our preclinical studies provided the basis for an ongoing clinical trial exploring the activity of HexaBody-DR5/DR5 (GEN1029) in patients with malignant solid tumors.
Organizational Affiliation:
Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton.
